St. Jude Medical (STJ) Announces Launch of QuickOpt Timing Cycle Optimization for CRT-D in Japan
More News related to STJ
- Relator's Attorneys Comment On AtriCure/DOJ Proposed Settlement
- St. Jude Medical To Present at the 2009 Credit Suisse Healthcare Conference
- Don't Miss Out! The Registration Period for the 2010 IR Global Rankings Ends TOMORROW!
- Time Is Running Out to Have Your IR Program Independently Evaluated!
- St. Jude Medical (STJ) Announces $500M Share Buyback
More News related to Corporate News
- S&P Announces Changes to US Index: CMN for NTG, CVGW for STSA
- Kinross (KGC) Enters Agreement for $125M Letter of Credit Facility
- Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
- Trubion Pharma (TRBN) Announces Two Presentations of TRU-016 Product at 2009 ASH Meeting
- S&P Revises Outlook on Sirius XM (SIRI) from Stable to Positive
St. Jude Medical, Inc. (NYSE: STJ) today announced expanded approval from the Japanese Ministry of Health, Labour and Welfare for the QuickOpt(R) Timing Cycle Optimization feature in the Epic(R) HF and Atlas(R)+ HF cardiac resynchronization therapy defibrillators. CRT-Ds are implantable cardioverter defibrillators that help prevent sudden cardiac arrest and treat heart failure by synchronizing heart rhythms.
The QuickOpt capability allows physicians to easily test and optimize a patient's CRT-D to ensure that its pacing rhythm is customized to the individual patient's needs. This is important because heart disease is different in each patient, so optimizing the devices helps to ensure that each patient receives the full benefit of device therapy.
St. Jude Medical, Inc. designs, manufactures, and distributes cardiovascular medical devices and implantable neurostimulation devices worldwide.
Related Categories
Corporate NewsStocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
